United States  

CytoDyn says that independent safety review of Phase 3 leronlimab trials found no concerns

Proactive Investors Tuesday, 4 August 2020
CytoDyn Inc (OTCQB:CYDY) announced Tuesday that an independent safety review of its ongoing Phase 3 clinical trial of leronlimab found no concerns and recommended the trial continue. The review was conducted by the Data Safety Monitoring Committee (DSMC), which looked at compiled safety data from 149 patients enrolled in the trial. Leronlimab is being studied as a potential treatment for the coronavirus (COVID-19). The treatment was previously granted Fast Track designation by the US Food and Drug Administration for the treatment of HIV in combination with highly active antiretroviral therapy (HAART), and for metastatic triple-negative breast cancer, a rare variety which doesn’t respond to some treatments.  READ: CytoDyn says FDA seeks more information to complete a review for leronlimab as a combination therapy for HIV patients Vancouver, Washington-based CytoDyn has 169 enrolled patients in its Phase 3 study and will conduct a full interim analysis once 195 patients are enrolled, as provided in the trial’s protocol, it said in a release Tuesday. In a statement, CEO Nader Pourhassan thanked the DSMC for its “diligence, guidance and support. “We are grateful to be less than 30 patients away from our planned interim analysis enrollment goal, and we look forward to sharing those interim efficacy results as soon as possible.”   The Phase 3 randomized, double blind, placebo controlled, adaptive design multicenter two arm study is designed to evaluate the safety and efficacy of leronlimab in patients with severe or critical symptoms of respiratory illness caused by COVID-19. Patients are randomized 2:1 (two leronlimab: one placebo) to receive weekly doses of 700 milligrams leronlimab or placebo through subcutaneous injection.  Chief scientific officer Jacob Lalezari added that the firm “eagerly awaits” the results of the pending full interim analysis of CD12, as well as the complete safety and efficacy results from CD10, a recently completed study of patients with mild to moderate COVID-19 illness. “We are very pleased the DSMC reported no safety concerns in CD12, a population with very severe illness and comorbidities at study entry,” Lalezari said in a statement. “We believe these results will provide compelling proof of efficacy and soon provide the world with a broadly effective therapeutic option for this devastating pandemic.” Contact Angela at [email protected] Follow her on Twitter @AHarmantas  
Video Credit: Motorcyclist Magazine - Published
News video: 2020 GasGas TXT Racing 250 First Ride Review

2020 GasGas TXT Racing 250 First Ride Review 06:58

Trials motorcycles offer a riding experience unlike anything else on two wheels. These competition-spec machines are designed to traverse crazy obstacles, whether they’re boulders, huge logs, or monster truck tires. This genre of motorcycle is capable of crazy acrobatics that most wouldn’t think...

You Might Like

Related videos from verified sources

Second national sero-survey to be completed in September first week: ICMR [Video]

Second national sero-survey to be completed in September first week: ICMR

Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said,..

Credit: ANI     Duration: 01:49Published
Mercedes E-Class Facelift Full Review [Video]

Mercedes E-Class Facelift Full Review

Hardly any other vehicle represents the Mercedes brand as much as the E-Class. The top selling upper middle Class has been updated for the 2020 model year. In addition to new engines and a revised..

Credit: News2do     Duration: 13:29Published
Out of 3 COVID vaccines, one will enter in phase 3 trial: NITI Aayog [Video]

Out of 3 COVID vaccines, one will enter in phase 3 trial: NITI Aayog

Member of NITI Aayog, VK Paul on August 18 informed that three vaccines of COVID-19 are being developed in India among which one of them will enter in phase 3 trial today or tomorrow and other 2 are in..

Credit: ANI     Duration: 01:36Published

Related news from verified sources

CytoDyn reaches patient quota for Phase 3 leronlimab coronavirus trial; analysis expected in four weeks

CytoDyn Inc (OTCQB:CYDY) announced Tuesday that it has enrolled the requisite 195 patients in its Phase 3 trial of leronlimab in severe-to-critical coronavirus...
Proactive Investors

CytoDyn to submit leronlimab application questions to FDA; gets nod from UK regulators to proceed with coronavirus trial

CytoDyn Inc (OTCQB:CYDY) has announced a pair of regulatory advancements for its drug leronlimab as a treatment for HIV and the coronavirus (COVID-19) both in...
Proactive Investors